In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma concentrations.
Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling
One of the critical components of the respiratory drug delivery is the manner in which the inhaled aerosol is deposited in respiratory tract compartments.
Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs.
Prediction of local exposure following inhalation of a locally acting pulmonary drug is central to the successful development of novel inhaled medicines, as well as generic equivalents.
Data Projects Medical Technologies Market to Expand
FinancialBuzz.com News Commentary
Converting In Vitro Permeability to Effective Jejunum Permeabililty
This video is a demonstration of Tutorial 5.3.3. It shows how to create a correlation between apparent permeability and effective jejunum permeability.
In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials
Current strategies to delineate the risk of serious drug-induced liver injury associated with drugs rely on assessment of serum biomarkers that have been utilized for many decades.
Cognitive Engineering – The Tools, Mindset, and Strategy for an Integrated Development Standard
Internet technology facilitates connectedness but often fails to foster collaboration. Advanced modeling techniques can provide insight for development discussions, but in many cases, these tools…
Pharmacokinetic Analysis of Gatilfoxacin in Plasma and Sinus Aspirate Drug Treatment of Maxiliary Sinusitis
A novel approach to collect sinus exudate was utilized and the time course of gatifloxacin (GAT) in the blood and at the primary infection site were assessed during treatment for acute maxillary sinusitis (AMS).
A framework for 2-stage global sensitivity analysis of GastroPlus™ compartmental models
Parameter sensitivity and uncertainty analysis for physiologically based pharmacokinetic (PBPK) models are becoming an important consideration for regulatory submissions, requiring further...
Food effects in paediatric medicines development for products Co-administered with food
A small amount of food is commonly used to aid administration of medicines to children to improve palatability and/or swallowability.
Pharmacokinetics And Exposure-Response Relationships Of Dasotraline In The Treatment Of Attention-Deficit/Hyperactivity Disorder In Adults
To characterize the pharmacokinetic and pharmacodynamic data to explore the time course and exposure response relationships in Phase 2 to define dasotraline benefit to risk relationship in adult Attention...
Characterization of Population Pharmacokinetics of Cariprazine and Its Major Metabolites
Population pharmacokinetic (PK) analysis was undertaken to describe the concentration‑time profiles of cariprazine and its 2 major metabolites of similar pharmacological activity, desmethyl‑cariprazine...
Dermal pharmacokinetics of pyrazinamide determined by microdialysis sampling in rats
Studies have demonstrated pyrazinamide's efficacy against stages of the parasite which causes cutaneous leishmaniasis. Although pyrazinamide is widely distributed to most...
Simulations Plus Launches Version 2.0 of PKPlus™
Major update to preclinical and clinical trial data analysis software addresses user requests
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
Sapanisertib (TAK-228) is an investigational, orally available, potent and highly selective mTORC1/2 inhibitor demonstrating promise in numerous malignancies.
What’s New in DILIsym® v7A?
Learn about the new features in DILIsym v7A that provide important new capabilities to enable our customers to better assess the potential for liver damage from new and existing drug compounds.
Physiologically-Based Pharmacokinetic Modeling in Lead Optimization II: “Rational Bioavailability Design” by Global Sensitivity Analysis to Identify Properties Affecting Bioavailability.
When medicinal chemists need to improve oral bioavailability (%F) during lead optimization, they systematically modify compound properties mainly based on their own experience and general rules of thumb.